News about Ingredients

Actimed Therapeutics receives S-pindolol patent in the UK

Actimed Therapeutics receives S-pindolol patent in the UK

Actimed Therapeutics Ltd, a clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, announced the grant of a new UK Patent (GB 2593902 B) covering new salts of S-pindolol for use in the treatment or prevention of cachexia with an expiry date in 2040.

Ingredients | 05/05/2022 | By Sudeep Soparkar

Duchenne gene therapy trials resumed

Duchenne gene therapy trials resumed

Pfizer is set to resume its late-stage clinical trials of a treatment for Duchenne muscular dystrophy after stopping in December because of a clinical hold.

Ingredients | 02/05/2022 | By Sudeep Soparkar

Fennec's NDA approved by FDA

Fennec's NDA approved by FDA

The U.S. FDA has accepted Fennec Pharmaceuticals resubmitted new drug application (NDA) for Pedmark, a drug aimed at preventing hearing loss in children who receive platinum-based chemothera

Ingredients | 30/04/2022 | By Sudeep Soparkar

Schizophrenia and bi-polar drug gets FDA approval

Schizophrenia and bi-polar drug gets FDA approval

The U.S. FDA has approved a new drug from BioXcel used to treat patients with schizophrenia or bipolar I or II disorder. BioXcel?s drug Igalmi was developed using the company?s artificial intelligence platform, marking a big step for the technology in the pharmaceutical industry, according to BioXcel.

Ingredients | 27/04/2022 | By Sudeep Soparkar

Regeneron's Covid treatment review extended by FDA

Regeneron's Covid treatment review extended by FDA

The U.S. FDA is broadening the survey date for Regeneron Pharmaceuticals' COVID-19 immune response mixed drink back by 90 days. The choice was made after information showed it might assist with forestalling disease.

Ingredients | 16/04/2022 | By Sudeep Soparkar

Neem extract has antiviral properties against coronavirus, finds IISER researchers

Neem extract has antiviral properties against coronavirus, finds IISER researchers

Researchers from Indian Institute of Science Education and Research (IISER) Kolkata during their research have found that Neem extract derived from the bark of Neem tree has the antiviral properties against coronavirus and can be used to treat and reduce the spread of SARS-Cov-2 that is causing the deadly Covid-19 disease among the people

Ingredients | 06/03/2022 | By Darshana

Quotient Sciences completes integration of drug substances into translational pharmaceuticals platform

Quotient Sciences completes integration of drug substances into translational pharmaceuticals platform

The full integration of drug substance R&D and manufacturing follows a year after the company's acquisition of its Alnwick, UK site and provides a more streamlined approach from candidate selection through to commercialization. Quotient Sciences Translational Pharmaceutics approach combining manufacturing and clinical dosing at a single organization

Ingredients | 18/02/2022 | By Darshana

Government approves PLI scheme to boost domestic API production: Dr Mansukh Mandaviya

Government approves PLI scheme to boost domestic API production: Dr Mansukh Mandaviya

With a view to attain self-reliance and reduce import dependence in critical APIs, the Centre has approved ?Production Linked Incentive (PLI) scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) In India

Ingredients | 23/12/2021 | By Darshana

Panacea Biotec supplies maiden shipment of Sputnik V's second component produced in India

Panacea Biotec supplies maiden shipment of Sputnik V's second component produced in India

The Russian Direct Investment Fund (RDIF) and Panacea Biotec have announced the supply of the first shipment out of one million doses of the second component (human adenovirus serotype 5) of the Russian Sputnik V coronavirus vaccine manufactured by Panacea Biotec for sale in India, the company said in a statement

Ingredients | 08/09/2021 | By Darshana 111

AffaMed inks agreement with Beijing Tiantan Hospital & IBT to promote & develop digital therapy in neurological diseases

AffaMed inks agreement with Beijing Tiantan Hospital & IBT to promote & develop digital therapy in neurological diseases

AffaMed Therapeutics, a global clinical stage biopharmaceutical company, announced during the recent "China International Trade in Services Fair 2021" a strategic cooperation partnership with Beijing Tiantan Hospital of Capital Medical University and Beijing Infinite Brain Technologies (IBT)

Ingredients | 07/09/2021 | By Darshana

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology